Atrium Therapeutics, Inc. Common Stock (RNA) — Financial Flexibility Index
Atrium Therapeutics, Inc. Common Stock (RNA) has a Financial Flexibility Index of -0.26x as of December 2025. Free cash flow of $-18.37 Million (operating CF $-19.25 Million minus capex $879.00K) represents 0% of total liabilities ($71.07 Million). Check Atrium Therapeutics, Inc. Common Stock (RNA) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Atrium Therapeutics, Inc. Common Stock Financial Flexibility Index (2018–2025)
Historical Financial Flexibility Index trend for Atrium Therapeutics, Inc. Common Stock across 8 annual periods. For the full cash flow conversion analysis, see Atrium Therapeutics, Inc. Common Stock (RNA) cash conversion ratio.
Annual Financial Flexibility Index for Atrium Therapeutics, Inc. Common Stock (2018–2025)
Year-by-year free cash flow to debt coverage for Atrium Therapeutics, Inc. Common Stock. Explore Atrium Therapeutics, Inc. Common Stock (RNA) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.56x | $-39.68 Million | $-41.13 Million | $71.07 Million | ▲ +73.6% |
| 2024 | -2.11x | $-293.80 Million | $-300.87 Million | $138.94 Million | ▼ -135.3% |
| 2023 | -0.90x | $-114.84 Million | $-119.06 Million | $127.79 Million | ▲ +59.1% |
| 2022 | -2.20x | $-133.44 Million | $-136.27 Million | $60.73 Million | ▼ -11.4% |
| 2021 | -1.97x | $-91.07 Million | $-94.81 Million | $46.15 Million | ▼ -51.6% |
| 2020 | -1.30x | $-36.02 Million | $-37.12 Million | $27.68 Million | ▼ -7851.3% |
| 2019 | 0.02x | $2.73 Million | $2.49 Million | $162.26 Million | ▲ +107.9% |
| 2018 | -0.21x | $-9.61 Million | $-9.65 Million | $45.11 Million | — |